ABSTRACT
CD70 is a member of TNFR (tumor necrosis factor receptor) super family, which is essential for maintaining immune response through controlling the activation, proliferation and differentiation of T cells and B cells. CD70 is highly expressed in various types of tumors which suggests that it may become a potentially effective target for immunotherapy. This paper summarizes the biological function and expression of CD70 in tumor tissues and the advances in research on the role of CD70 in antitumor therapy, so as to provide valuable references and evidence for the clinical application of CD70. Copyright © 2013 by TUMOR.
ABSTRACT
Stathmin, a ubiquitously expressed cytosolic protein(Mr=19×10~3), is also called oncogene protein 18 (Op18). Stathmin is involved in the assembly of microtubule (MT) and spindle by binding the tubulin protein. It plays a key role in cell proliferation, differentiation, regeneration, and migration and has regulatory effects on the signal transduction. Recently, it is reported that stathmin is overexpressed in a variety of human malignancies. It induces tumor cell migration and invasion by regulating MT depolymeri-zation. Its post-translational modification influences the interaction with p53 protein and is involved in the initiation and progression of malignant tumor. Stathmin alone or in combination with chemotherapeutics has been used for tumor therapy. The internal association of stathmin with cancer etiology is still unknown. So, further studies are needed to determine the role of stathmin as potential tumor biomarker and a drug target in tumor therapy.